Murex hiv ag ab combination

Manufactured by DiaSorin

Sourced in Japan, United Kingdom, France

The Murex HIV Ag/Ab Combination is a laboratory diagnostic test used for the detection of HIV-1 and HIV-2 antibodies and the HIV-1 p24 antigen in human serum or plasma samples. The test utilizes an enzyme immunoassay (EIA) principle to identify the presence of HIV-specific antibodies and antigens.

Automatically generated - may contain errors

Lab products found in correlation

Genscreen ultra hiv ag ab, by Bio-Rad (1 mentions) Anti hbc, by Abbott (1 mentions) Determine hiv 1 2, by Abbott (1 mentions) Real time pcr, by Abbott (1 mentions) Enzygnost hiv integral 4 elisa, by Siemens (1 mentions) Sd bioline hiv 1 2, by Standard Diagnostics (1 mentions) Uni gold hiv 1 2, by Trinity Biotech (1 mentions) Serodia hiv 1 2, by Fujirebio (1 mentions) Murex hbsag v 3, by DiaSorin (1 mentions)

5 protocols using murex hiv ag ab combination

Comprehensive Viral Serological Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The participants’ serum was tested using the Abbott ARCHITECT® automated immunologic assay platform and commercially available ARCHITECT assay kits for HCV antibody (anti-HCV) and HCV core antigen (HCVcoreAg), hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and hepatitis B core antibodies (anti-HBc) (Abbott Laboratories, USA). Specimens were initially screened for anti-HCV and HBsAg and with subsequent testing of reactive specimens for HCVcoreAg and HBeAg, respectively. Each run included standardized ARCHITECT® controls.
Blood specimens were tested for HIV per national guidelines: screening for HIV antibody using Genscreen Ultra HIV Ag/Ab (Bio-Rad, USA) with confirmation of positive tests by Determine HIV-1/2 (Alere, Japan) and Murex HIV Ag/Ab Combination (DiaSorin, United Kingdom of Great Britain and Northern Ireland) testing. The National Reference Laboratory at NIHE conducted external quality assurance on a randomly selected 10% of HIV-negative and 5% of HIV-positive screening samples.

Le L.V., O’Connor S., Tran T.H., Maher L., Kaldor J., Sabin K., Tran H.V., Tran Q.D., Ho V.A, & Nguyen T.A. (2019). High hepatitis C virus infection among female sex workers in Viet Nam: strong correlation with HIV and injection drug use. Western Pacific Surveillance and Response Journal : WPSAR, 10(3), 9-18.

+ Open protocol

+ Expand

Viral Coinfection Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Blood was drawn to test for viral co-infections at the time of enrollment in the study. HIV–Analysis for HIV-1 and HIV-2 antibodies was performed by enzyme linked immuno sorbent assay (ELISA) with Murex HIV Ag/Ab combination (DiaSorin, Dartfort, UK). Confirmatory testing was done with Western Blot analysis. HTLV–Sera with HTLV-1 diagnosis by ELISA (Cambridge Biotech Corp., Worcester, MA) were confirmed by Western Blot analysis. HBV–Hepatitis B core antigen (HBc) total antibodies was determined using an Anti-HBc Architect System (Abbott Laboratories. Abbott Park, Illinois, U.S.A). HCV–HCV IgG antibodies was determined using an Anti-HCV Architect System (Abbott Laboratories. Abbott Park, Illinois, U.S.A). HCV RNA was determined by RealTime PCR (Abbot Laboratories. Abbott Park, Illinois, U.S.A).

Machado P.R., Machado L.M., Shibuya M., Rego J., Johnson W.D, & Glesby M.J. (2015). Viral Co-infection and Leprosy Outcomes: A Cohort Study. PLoS Neglected Tropical Diseases, 9(8), e0003865.

+ Open protocol

+ Expand

Comprehensive STI Testing Protocol

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

The HIV testing procedure was based on rapid tests performed at the study site by a trained laboratory scientist and verified in the Microbiology and Immunology laboratory at MUHAS. The Tanzanian HIV testing algorithm^{21 (link)} was applied, which uses 2 sequential HIV rapid tests, SD Bioline HIV 1/2 (Standard Diagnostics Inc, the Republic of Korea) for screening and Uni-Gold HIV 1/2 (Trinity Biotech, Ireland) for confirmation of infection. Participants who were reactive to both HIV rapid tests were regarded as HIV infected. Enzyme-linked immunosorbent assay (ELISA) tests, Murex HIV Ag/Ab Combination (DiaSorin S.p.A., UK Branch), and Enzygnost HIV Integral 4 ELISA (Siemens Healthcare, Germany) were used to resolve discordant results between the 2 HIV rapid tests.
Syphilis testing was performed using a Laborex rapid treponemal assay (Orient Gene Biotech Co Ltd, Zhejiang, China), and all reactive samples were confirmed on a Treponema pallidum hemagglutination assay (TPHA, Chronolab, Barcelona, Spain). All reactive rapid hepatitis B and C test samples were confirmed using Murex Hepatitis B and Hepatitis C ELISAs (DiaSorin S.p.A., Italy), respectively. A urine pregnancy testing was performed every 6 months by detection of β-human chorionic gonadotrophin (β-HCG) using Laborex pregnancy rapid test (Orient Gene Biotech Co Ltd, Zhejiang, China).

Faini D., Msafiri F., Munseri P., Bakari M., Lyamuya E., Sandström E., Biberfeld G., Nilsson C., Hanson C, & Aboud S. (2022). The Prevalence, Incidence, and Risk Factors for HIV Among Female Sex Workers—A Cohort Being Prepared for a Phase IIb HIV Vaccine Trial in Dar es Salaam, Tanzania. Journal of Acquired Immune Deficiency Syndromes (1999), 91(5), 439-448.

+ Open protocol

+ Expand

HIV Serostatus Determination Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Wives previously testing HIV-negative as well as wives not yet tested for HIV serology were tested to determine initial HIV serostatus at the time of enrolment. The tests were performed at the Microbiology Department at BMH. An HIV-positive diagnosis was made when serum tested positive in the screening test (Alere Determine HIV-1/2, Alere Medical Japan, Japan) and two different anti-HIV antibody enzyme-linked immunosorbent assays following the official diagnostic protocol of the Ministry of Health of Vietnam [12 ]. Either of the two following kits were used: Genscree ULTRA HIV Ag-Ab, Bio-Rad Laboratories, France; Murex HIV Ag/Ab Combination, DiaSorin Dartford, UK; Serodia HIV-1/2, Fujirebio Inc., Japan; and Roche Elecsys HIV Combi, Roch Diagnostics, Germany.

Sawada I., Tanuma J., Do C.D., Doan T.T., Luu Q.P., Nguyen L.A., Vu T.V., Nguyen T.Q., Tsuchiya N., Shiino T., Yoshida L.M., Pham T.T., Ariyoshi K, & Oka S. (2015). High Proportion of HIV Serodiscordance among HIV-Affected Married Couples in Northern Vietnam. PLoS ONE, 10(4), e0125299.

+ Open protocol

+ Expand

HCV and HBV Serological Screening Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols

Laboratory and diagnostic methods have been described in detail previously.⁸ In summary, stored specimens from MSM surveyed underwent HCV Ag/Ab (Murex HCV Ag/Ab Combination, DiaSorin, Italy) and hepatitis B surface antigen (HBsAg) (Murex HBsAg V.3, DiaSorin) testing.¹⁸ A non-random selection of the HCV Ag/Ab+ specimens from MSM and, for comparison, from PWID specimens from the same survey⁹ underwent in-house real-time quantitative PCR for HCV RNA followed by 5′ untranslated region (UTR) sequencing of HCV RNA+ specimens. HCV genotyping was performed by amplification of the 5′ UTR fragment (nt 70–300) followed by Sanger sequencing and phylogenetic analysis in the presence of relevant reference strains collected from GenBank.
HIV status was determined using Genscreen HIV Ultra HIV Ag/Ab (Bio-Rad) to screen for antibodies to HIV; HIV-seropositive specimens were confirmed by using Determine HIV ½ (Alere) and Murex HIV Ag/Ab Combination (DiaSorin). Serologic testing was performed at the National Reference Laboratory on HIV at NIHE in Hanoi. HCV and HBV genotyping and quality assurance testing were performed by the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia.

Clow P.A, & McNally J.G. (1999). In Vivo Observations of Myosin II Dynamics Support a Role in Rear Retraction. Molecular Biology of the Cell, 10(5), 1309-1323.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!